Polyethylene glycol-coated collagen patch (hemopatch^®) in open partial nephrectomy.

Area of Science:

• Urology
• Surgical Innovation
• Oncology

Background:

• Partial nephrectomy (PN) is a standard treatment for renal cell carcinoma (RCC).
• Minimizing blood loss and operative time is crucial for patient recovery and renal function preservation.
• Hemostatic agents are often employed to manage bleeding during complex surgical procedures.

Purpose of the Study:

• To evaluate the efficacy of Hemopatch®, a polyethylene glycol-coated collagen patch, in reducing blood loss and surgical time during PN for RCC.
• To assess the impact of Hemopatch® on renal function post-PN.
• To compare outcomes between conventional PN (CPN) and PN using Hemopatch® (HPN).

Main Methods:

• A cohort of 42 patients undergoing PN with Hemopatch® (HPN) was compared to 565 patients undergoing conventional PN (CPN).
• Data collected included patient demographics, tumor characteristics, blood loss, surgical duration, and renal function (CKD-EPI).
• Statistical analysis was performed to compare outcomes between the HPN and CPN groups.

Main Results:

• The HPN group demonstrated significantly lower median blood loss (114 ml ± 159 ml) compared to the CPN group (146 ml ± 195 ml) (p=0.021).
• Surgical duration was also significantly shorter in the HPN group (43 min ± 27 min) versus the CPN group (53 min ± 49 min) (p=0.035).
• No significant difference was observed in renal clamping time or a significant decline in renal function post-surgery.

Conclusions:

• Hemopatch®-supported renoraphy shows promising results in partial nephrectomy, leading to reduced blood loss and surgical time.
• No adverse side effects were reported with the use of Hemopatch®.
• Hemopatch® should be considered for complex partial nephrectomies, with further studies recommended to investigate its role in preventing fistulas.